Market Overview

The global single-use bioreactors market is undergoing rapid expansion as biopharmaceutical manufacturers increasingly adopt flexible, scalable, and contamination-controlled manufacturing platforms.

According to the market report, the single-use bioreactors market is projected to grow from USD 5.43 billion in 2026 to USD 9.58 billion by 2031, registering a CAGR of 12.0% during the forecast period.

Single-use bioreactors have become an important component of modern upstream bioprocessing because they can reduce cleaning and sterilization requirements, support faster facility changeovers, and enable manufacturers to operate multiproduct production environments with greater flexibility.

The technology is increasingly used across monoclonal antibodies (mAbs), recombinant proteins, vaccines, biosimilars, viral vectors, cell & gene therapies (CGT), and other advanced biologics.

Growing investment in biologics development, expansion of outsourced bioprocessing, increasing demand for flexible manufacturing capacity, and advances in process intensification are creating strong opportunities for single-use bioreactor suppliers.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=49113750

What Is Driving the Single-Use Bioreactors Market?

1. Rapid Expansion of Biologics Manufacturing

Biologics represent one of the most important growth engines for the biopharmaceutical industry.

The development and commercialization of monoclonal antibodies, recombinant proteins, vaccines, biosimilars, and advanced therapies require sophisticated upstream manufacturing infrastructure.

Single-use bioreactors provide manufacturers with flexible cultivation platforms that can be configured for different production requirements.

Unlike traditional stainless-steel systems, disposable bioprocessing platforms can reduce the need for extensive cleaning and sterilization between batches, potentially shortening turnaround times and simplifying multiproduct operations.

As biologics pipelines continue to expand, demand for scalable single-use upstream processing solutions is expected to increase.

2. Growing Adoption of Biosimilars

The increasing development and commercialization of biosimilars is creating additional demand for efficient biomanufacturing infrastructure.

Biosimilar manufacturers need flexible production platforms capable of supporting process development, scale-up, validation, and commercial manufacturing.

Single-use systems can be particularly attractive in environments where manufacturers need to produce multiple biologic products at different scales.

3. Rising Investment in Cell & Gene Therapies

Cell and gene therapies are creating new requirements for flexible and adaptable manufacturing systems.

These therapies can involve complex production workflows, smaller batch sizes, high-value products, and stringent contamination-control requirements.

Single-use bioreactors can support several stages of advanced therapy development and manufacturing, particularly where closed processing, process flexibility, and reduced cross-contamination risk are important.

As the number of cell and gene therapy programs increases, demand for specialized single-use bioprocessing equipment is expected to rise.

Single-Use Bioreactor Systems Dominate the Product Segment

Based on product, the single-use bioreactors market is segmented into single-use bioreactor systems, single-use bags, single-use assemblies, and other products.

The single-use bioreactor systems segment accounted for the largest market share in 2025.

The segment benefits from the higher unit value of complete bioreactor systems, an expanding installed base, and increasing adoption across both process development and commercial manufacturing.

Single-use bioreactor systems are further categorized by scale into:

• ≤10 L
• 11–100 L
• 101–500 L
• 501–1,500 L
• ≥1,500 L

Among these, the 501–1,500 L category accounted for the largest share in 2025.

This scale range provides an effective balance between production capacity, scalability, and operational flexibility, making it suitable for clinical and commercial manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and biosimilars.

For multiproduct facilities, these systems can provide manufacturers with the ability to adjust production capacity while maintaining flexible manufacturing workflows.

Why Is Perfusion/Continuous Processing Growing Rapidly?

Based on process mode, the market is segmented into batch, fed-batch, and perfusion/continuous processing.

The perfusion/continuous process mode is estimated to register the highest growth rate during the forecast period.

Perfusion enables continuous media addition and product removal while retaining cells within the bioreactor. This can support high-cell-density cultivation, increased volumetric productivity, and extended production runs.

The growing emphasis on process intensification is encouraging manufacturers to explore perfusion-based workflows that can potentially increase output without proportionally expanding facility footprints.

Advances in cell-retention technologies, process monitoring, automation, sensors, and perfusion-ready single-use bioreactors are further supporting adoption.

The technology is particularly relevant to applications involving:

• Monoclonal antibodies
• Recombinant proteins
• Viral vectors
• Cell and gene therapies
• High-density cell culture

As biomanufacturers seek to increase productivity while optimizing facility utilization, perfusion and continuous processing are expected to become increasingly important.

Single-Use Technology Enables Flexible Biomanufacturing

One of the strongest advantages of single-use bioreactors is their ability to support flexible and modular manufacturing environments.

Traditional stainless-steel facilities can require substantial infrastructure for cleaning, sterilization, water systems, and validation.

Single-use platforms replace many reusable product-contact components with disposable systems, potentially simplifying facility design and reducing changeover requirements.

This is particularly valuable for multiproduct manufacturing facilities, clinical-stage production, contract development and manufacturing organizations (CDMOs), and emerging biotechnology companies.

Flexible infrastructure can help manufacturers respond more quickly to changing production requirements and varying batch sizes.

Integration With Single-Use Bags and Assemblies

Single-use bioreactors operate as part of a broader disposable bioprocessing ecosystem.

The market includes products such as single-use bags, fluid-transfer assemblies, sensors, connectors, sampling systems, and process control components.

The integration of these components can help create more closed and controlled upstream workflows.

Single-use bags are available in different configurations, including 2D and 3D formats, depending on the application and system design.

The increasing use of preassembled and customized disposable components is also helping manufacturers streamline setup and reduce manual intervention.

Digitalization and Automation Are Transforming Upstream Processing

The future of single-use bioreactor manufacturing is increasingly connected to automation, process analytical technology (PAT), sensors, and digital bioprocessing.

Modern bioreactor systems can incorporate sensors and controllers for monitoring critical process parameters such as:

• pH
• Dissolved oxygen
• Temperature
• Pressure
• Agitation
• Gas flow
• Feed rates
• Cell culture conditions

Automated monitoring can improve process consistency and provide manufacturers with greater visibility into upstream cultivation.

The integration of real-time data with manufacturing execution systems and analytical platforms could further support data-driven process optimization.

CDMOs and Outsourced Bioprocessing Create New Demand

The expansion of contract development and manufacturing organizations (CDMOs) is another major market driver.

Biotechnology companies increasingly outsource process development, scale-up, clinical manufacturing, and commercial production to specialized service providers.

CDMOs require manufacturing platforms that can accommodate:

• Multiple clients
• Multiple products
• Different batch sizes
• Rapid technology transfer
• Clinical and commercial production
• Flexible facility utilization

Single-use bioreactors are well suited to these requirements because of their flexibility and scalability.

As pharmaceutical and biotechnology companies increasingly rely on outsourcing, CDMOs are expected to remain important buyers of single-use bioreactor systems and associated consumables.

North America Held the Largest Market Share

North America accounted for the largest share of the single-use bioreactors market in 2025.

The region benefits from a mature biopharmaceutical ecosystem, substantial biologics R&D activity, extensive CDMO capabilities, and early adoption of disposable manufacturing technologies.

The US is the primary contributor to regional growth because of its extensive pipeline of:

• Monoclonal antibodies
• Vaccines
• Recombinant proteins
• Viral vectors
• Cell and gene therapies
• Biosimilars

Continued investment in modular facilities and flexible commercial-scale manufacturing is supporting demand for single-use systems, bags, assemblies, sensors, and controllers.

The presence of major bioprocessing technology suppliers and advanced manufacturing infrastructure further strengthens North America’s position.

Asia Pacific Represents a Major Long-Term Opportunity

Although North America currently leads the market, Asia Pacific represents an important growth opportunity.

The region’s expanding biopharmaceutical manufacturing sector, increasing investment in biologics, growing outsourcing activity, and development of domestic biotechnology capabilities are supporting adoption of single-use technologies.

Countries such as China, India, Japan, South Korea, and Singapore are strengthening their biopharmaceutical manufacturing ecosystems.

As manufacturers in the region invest in flexible facilities and advanced upstream processing capabilities, demand for single-use bioreactors and related consumables is expected to increase.

Key Technology Trends Through 2031

Several trends will influence the development of the single-use bioreactors market.

Process Intensification

Manufacturers are increasingly seeking technologies that can produce higher yields from smaller facility footprints. Perfusion and high-cell-density cultivation are central to this trend.

Closed Processing

Closed and functionally closed workflows can help improve contamination control and process consistency.

Modular Manufacturing

Modular facilities can provide greater flexibility in capacity expansion and production configuration, particularly for rapidly growing biologics companies.

Advanced Automation

Automated control systems and real-time monitoring are expected to become increasingly important as manufacturers seek greater process consistency.

High-Performance Materials

Advances in polymer films, bag durability, mixing technologies, and oxygen transfer are expanding the performance capabilities of single-use systems.

Digital Bioprocessing

The integration of sensors, software, analytics, and connected equipment is creating increasingly data-driven upstream manufacturing environments.

Competitive Landscape

The single-use bioreactors market includes major bioprocessing, life sciences, filtration, fluid management, and manufacturing technology companies.

Key players include Sartorius AG, Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Avantor, Repligen Corporation, Getinge AB, Eppendorf SE, Parker Hannifin Corporation, Entegris, Saint-Gobain, Corning Incorporated, Lonza, TECNIC Process Equipment Manufacturing, ZACROS Corporation, Adolf Kühner AG, OmniBRx Biotechnologies, New Horizon Biotechnology, PBS Biotech, bbi-biotech, ABEC, Esco Lifesciences Group, Distek, SATAKE MultiMix, Cell Culture Company, MicroDigital, BIONET, Meissner Filtration Products, Solida Biotech, G&G Technologies, PharmNXT Biotech, and Tofflon Life Science, among others.

Competition is increasingly focused on system scalability, mixing performance, oxygen transfer, automation, process control, bag quality, sensor integration, contamination control, and compatibility with intensified manufacturing workflows.

Companies capable of providing complete single-use ecosystems rather than standalone equipment may have an advantage as biomanufacturers seek integrated solutions.

Strategic Opportunities for Market Participants

1. High-Growth Biologics

The continued development of monoclonal antibodies, recombinant proteins, vaccines, and biosimilars will sustain demand for scalable upstream systems.

2. Cell & Gene Therapy Manufacturing

Advanced therapies offer opportunities for specialized single-use bioreactor platforms designed around smaller batches, closed processing, and highly controlled workflows.

3. Perfusion Technologies

The rapid growth of perfusion and continuous processing provides opportunities for companies developing cell-retention technologies, sensors, control systems, and high-performance bioreactors.

4. CDMO Partnerships

As outsourcing expands, suppliers can develop strategic partnerships with CDMOs to provide standardized and customizable single-use manufacturing platforms.

5. Digital Integration

Connected bioreactors with advanced monitoring and analytics can create additional value through improved process visibility, predictive maintenance, and process optimization.

Single-Use Bioreactors Market: Key Takeaways

Market Size, 2026: USD 5.43 billion
Projected Market Size, 2031: USD 9.58 billion
CAGR: 12.0%
Largest Product Segment: Single-use bioreactor systems
Largest System Scale: 501–1,500 L
Fastest-Growing Process Mode: Perfusion/continuous
Largest Regional Market: North America
Key Applications: Monoclonal antibodies, vaccines, recombinant proteins, viral vectors, and cell & gene therapies
Key Growth Drivers: Biologics expansion, biosimilar development, CGT investment, CDMO growth, process intensification, modular facilities, and digital bioprocessing

Market Outlook

The single-use bioreactors market is positioned for strong expansion as biopharmaceutical manufacturing moves toward greater flexibility, faster changeovers, intensified processes, closed workflows, and digitally connected production.

The projected growth from USD 5.43 billion in 2026 to USD 9.58 billion by 2031, at a 12.0% CAGR, reflects the increasing strategic importance of single-use technologies in modern biomanufacturing.

The strongest opportunities will likely emerge at the intersection of biologics production, cell and gene therapy, perfusion processing, CDMO outsourcing, process intensification, and automation.

Conclusion

Single-use bioreactors are becoming a foundational technology for flexible biopharmaceutical manufacturing.

The combination of expanding biologics pipelines, increasing biosimilar development, growing investment in cell and gene therapies, rising CDMO activity, and the industry’s transition toward modular and intensified production is creating sustained demand.

While North America currently holds the largest market share, global adoption is expected to broaden as Asia Pacific and other emerging biopharmaceutical manufacturing hubs expand their production capabilities.

The next phase of market development will be shaped by higher-capacity systems, advanced perfusion technologies, improved disposable materials, sophisticated sensors, automation, and digital process control.

For bioprocessing technology companies and manufacturers, the opportunity extends beyond the bioreactor itself. Integrated ecosystems encompassing single-use bags, assemblies, sensors, controllers, fluid management, automation, and process analytics are likely to become increasingly important as the industry moves toward smarter and more flexible biomanufacturing.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=49113750